BiotechTube
Mission Bio

Mission Bio

South San Francisco, United States· Est.
missionbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $110M

Overview

Mission Bio is a private, commercial-stage company offering a unique single-cell multi-omics platform called Tapestri. The platform enables researchers to analyze DNA mutations (SNV/CNV) and protein expression from the same cell, providing high-resolution insights into clonal heterogeneity in cancer and the outcomes of genome editing. Founded in 2014, the company targets the research and translational oncology market, with a growing focus on clinical biomarker discovery and partnerships with biopharma to advance precision medicine.

OncologyHematologic MalignanciesSolid Tumors

Technology Platform

Tapestri Platform: A single-cell multi-omics platform that simultaneously measures DNA (SNVs and CNVs) and protein from the same cell using microfluidics, barcoding, and targeted NGS.

Funding History

3
Total raised:$110M
Series C$70M
Series B$30M
Series A$10M

Opportunities

The growing demand for single-cell analysis in precision oncology and the rapid expansion of the cell and gene therapy market present significant opportunities.
Mission Bio's platform is uniquely positioned to become a standard tool for characterizing tumor heterogeneity and for quality control in CRISPR-based therapies, opening doors to biopharma partnerships and potential companion diagnostic pathways.

Risk Factors

Key risks include intense competition in the single-cell genomics space from larger, well-capitalized players, potential challenges in driving widespread adoption of a complex multi-omics workflow, and dependence on the research tools market which may require significant investment to transition into clinical diagnostics.

Competitive Landscape

Mission Bio competes in the single-cell analysis market against major players like 10x Genomics (strong in single-cell RNA-seq and spatial biology) and Bio-Rad/Standard BioTools. Its primary differentiation is the simultaneous detection of DNA mutation and protein data from the same cell, a niche not fully addressed by competitors who often offer separate solutions for genomics and proteomics.

More companies in Diagnostics & Precision Medicine →More companies in United States →